Economic evaluation of Avonex® (interferon beta-1a) in patients following a single demyelinating event

Abstract

Avonex may be considered as a reasonably cost-effective approach to treatment of patients experiencing an SDE In addition, the overall incremental cost-effectiveness profile of Avonex improves if treatment is initiated in pre-CDMS rather than waiting until CDMS.